"Where Everyone Has an MBA"
Tel: (612) 246-4616
Frequently Asked Questions
- Frequently Asked Questions
- User Testimonials
XBiotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for XBiotech Inc
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
- Nov 17th, 2017 1:39 pm
Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark Diagnostics, Inc., Impax Laboratories, Inc., RPM International Inc. and XBiotech Inc.
- Nov 16th, 2017 4:08 pm
XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
- Nov 14th, 2017 5:31 am
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.
- Nov 8th, 2017 12:30 pm
XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
- Nov 3rd, 2017 10:18 am
IMPORTANT XBIOTECH, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas on behalf of investors who purchased and suffered losses in XBiotech, Inc.
- Nov 2nd, 2017 2:42 pm
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBIT
- Oct 26th, 2017 12:54 pm
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
- Oct 19th, 2017 9:57 am
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
- Oct 18th, 2017 8:41 am
XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
- Oct 3rd, 2017 6:00 am
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference
- Sep 21st, 2017 6:01 am
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
- Sep 20th, 2017 6:00 am
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.
- Sep 18th, 2017 4:16 pm
XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
- Sep 7th, 2017 6:00 am
Robbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action
- Jul 11th, 2017 10:25 am
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
- Jun 21st, 2017 1:43 pm
Frequently Asked Questions
Terms and Conditions
Copyright © 2017 VentureLine
Website developed by Digital Solutions